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Abstract
The oral cavity contains many different surfaces all colonized by prokaryotes, of
which over 700 have been identified. While almost all people have some degree of plaque
formation, the more concerning diseases of caries, candidiasis and periodontal disease afflict
many patients and represent a major public health concern. As these are all diseases which
have a component attributable to parts of the microbiota, efforts to manipulate the microbes
has until recently involved use of antimicrobial agents. However, due to side effects,
resistance and failure to restore homeostasis, this approach is limited. As an alternative, the
administration of beneficial microbes (probiotics) has been considered. In this thesis,
probiotic Streptococcus salivarius K12 and M18 and their by-products were shown to
interfere with adhesion and coaggregation of pathogenic bacteria and yeast, and lower
inflammatory factors. A human trial of healthy subjects showed the probiotics to be safe and
not induce inflammation or disrupt the indigenous microbiota.

Keywords: oral cavity, probiotic, Streptococcus salivarius, adhesion, inflammation,
coaggregation, humans
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Chapter 1
1

Introduction

1.1

Focus of Thesis
The purpose of this study was to investigate the ability of the human commensal

bacterial species Streptococcus salivarius to maintain homeostasis in the oral cavity. This
section will cover information on the human oral microbiome, how diseases develop as
this bacterial community shifts in composition, and how probiotics may offer promise in
preventing and treating these highly prevalent oral diseases, with specific emphasis
placed on the oral probiotic strains S. salivarius K12 and M18.

1.2

The Human Microbiome
The human body plays host to numerous bacterial populations which colonize and

persist at various sites including the skin, gastrointestinal tract, vagina, urogenital tract,
and oral cavity (1). These complex and diverse communities are established and
influenced based on a variety of factors such as the host's genetics, behaviours,
environment, and diet (2). The human microbiome, defined as the collective genomes of
our microbial constituents, provide additional metabolic functions above and beyond
what the human genome alone is capable of driving (3).

It has been increasingly

recognized that these microorganisms dynamically interact with the host in ways that can
have profound effects on health and disease (1, 2). Perhaps nowhere is the association of
commensal microbes with our well-being more apparent than in the oral cavity.
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1.3

Healthy Oral Microbiome
The oral cavity contains many different surfaces including the teeth, tongue,

cheeks, hard and soft palates, gingival sulcus (area of space between a tooth and the
surrounding gingival tissue), and tonsils, which are colonized by distinct and intricate
microbial communities (4). Early research focused on culturing the vast number of
bacterial species inhabiting this environment, with many aerobes as well as facultative
and obligate anaerobes isolated and identified. These organisms demonstrated a wide
range of metabolic processes, including the ability to degrade and utilize the complex
sugars and proteins consumed by their human host in their diet (5). However, it is well
established that a significant percentage of bacteria cannot be grown in the laboratory
using traditional culture methods (6). The advancement of non-culture based methods of
detection and classification in recent years, including high-throughput next generation
sequencing technologies, has shed light on the truly immense range of bacterial species
that colonize and persist in the human oral cavity (4, 7, 8). Approximately 700 oral
prokaryotic species have currently been identified, of which 34% are presently
uncultivated (4). The existence of such microorganisms is not unique to the oral cavity, as
uncultivated species have been shown to represent around 40-50% of the total taxa
colonizing the human skin, vagina, and stomach (9). Studies have identified a healthy
"core microbiome" consisting predominantly of taxa belonging to Firmicutes,
Proteobacteria, Actinobacteria, Bacteroidetes, and Fusobacteria phyla (10). These
commensals preserve homeostasis in the oral cavity by helping to produce nutrients,
maintain pH, modulate saliva production, and generate inhibitory substances, all of which
act to prevent colonisation and growth of exogenous or pathogenic species (11).
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1.4

Diseases caused by the Disruption of the Oral Microbiome
While the oral microbiome of an individual remains fairly stable over time (12),

problems arise when bacterial populations shift, allowing different metabolic processes to
occur, often resulting in a drastically altered local environment. The resulting oral
diseases can have a significant negative impact on the quality of life of the patient, and
often result in chronic conditions, particularly if access to dental professionals is limited.
Some of the most prevalent oral microbial associated diseases are summarized below.

1.4.1 Dental Caries
Dental caries (otherwise known as tooth decay or cavities) is one of the most
prevalent chronic diseases of people worldwide, with patients susceptible to developing
caries throughout their lifetime (13). This process is mediated by an increase in
acidogenic and/or acid-tolerating bacteria found in dental plaques (biofilms) on the teeth,
which ferment sugars into organic acids (14). The consequent reduction in pH catalyzes
the demineralization of enamel, dentin and cementum in teeth, resulting in caries lesions
(13). Production of short-chain carboxylic acids by Streptococci and Lactobacilli –
chiefly lactic acid production by Streptococcus mutans – is the primary etiology of caries,
however other bacteria with similar properties such as Actinomyces, Bifidobacteria,
Atopobium, Propionibacterium, and Veillonella can contribute (15).
Management of caries in dental practice has traditionally and mainly been carried
out through surgical methods (16). The demineralized/diseased tooth structure is removed
and restorative materials are applied to promote reformation. This, however, does not
remove the causative infectious agent. Broad-spectrum antibiotics and antimicrobials are
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occasionally used post-surgery to suppress further infection, however any success will be
temporary (16).

1.4.2 Oral Candidiasis
Oral candidiasis is a fungal infection of the oral cavity caused by various species
of yeast from the genus Candida. Candida species are frequently found in the oral cavity
of healthy individuals, with a recent study detecting the genera in 75% of participants
(17). The most common isolate found in humans is Candida albicans, which colonizes
the posterior dorsum of the tongue (18). While typically carried asymptomatically, C.
albicans can act as an opportunistic pathogen in patients with compromised oral health or
immune deficiencies, such as the elderly or transplant recipients (19). While oral lesions
caused by C. albicans infection can cause discomfort, in more serious cases the yeast can
gain access to the bloodstream and systemically spread (20). Proper oral hygiene
practices are important for controlling natural oral yeast populations, with antifungal
agents used as treatment once oral candidiasis has been established (19).

1.4.3 Periodontal Disease
Periodontal disease is characterized by inflammation of the tissues that surround
and support the teeth, including the gums and periodontal ligaments. It arises as a
consequence of long-term dental plaque build up on the teeth. This plaque is made up of
bacteria and food debris, which eventually turns into a hard deposit (tartar) if not
removed by regular brushing and flossing. The bacteria trapped in the tartar irritate the
gums, causing an overt immune response directed against them, leading to inflammation
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(21). Symptoms of periodontal disease include bleeding, swelling, and tenderness of the
gums. In more advanced cases, such as periodontitis, alveolar bone that surrounds and
supports the teeth is destroyed, which can lead to tooth loss. A recent study indicated that
approximately 50% of North American adults suffer from some form of periodontal
disease, making it a major public health concern (22).
During periodontal disease, the oral microbiota shifts

from a Gram-positive

dominated community to one comprised mainly of Gram-negative bacteria (23). Bacteria
classically considered to be strongly associated with periodontal disease include
Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, and Fusobacterium
nucleatum (24). These anaerobes trigger the release of pro-inflammatory cytokines,
leading to immune cell recruitment, tissue destruction, and eventual bone loss. Cytokines
important in this destructive cycle include IL-1β (bone resorption, metalloproteinase
production), IL-6 (B-cell activation), IL-8 (attraction and activation of neutrophils), TNFα (bone resorption), and IFN-γ (modulates local immune responses) (25).
When periodontal disease is diagnosed, plaque and tartar is typically removed by
a dental professional in a process known as "scaling". In more advanced cases, surgery
may be required to allow deep cleaning and reduce periodontal pocket depth. Newer
therapies aimed at periodontal regeneration include the use of soft tissue and bone grafts,
guided tissue/bone regeneration, and the delivery of growth factors by implanted
biomaterials (26). Management of periodontal disease typically requires multiple trips per
year to the dentist for cleanings, and even with regular home oral care inflammation may
return (21).
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1.4.4 Influence at Distant Sites
The effects of a disruption of the oral microbiome are not confined solely to the
oral cavity. Members of the oral microbiota can have a bearing upon heart health,
Streptococcus pyogenes being the classic example, where cross reactive antibodies affect
the heart valves and other parts of the body (27). Periodontal disease has been associated
with cardiovascular disease through a variety of epidemiological studies, and metaanalyses combining the findings from multiple independent studies conducted since the
1950's (28, 29). The increase in gingival bleeding during periodontal disease offers oral
bacteria access to the bloodstream, where they can circulate and interact with
atheromatous plaque deposits. Numerous studies have detected oral bacterial DNA in
atherosclerotic lesions (30). The bacteria appear capable of invading and activating
endothelial cells, increasing Toll-like receptor (TLR) interactions, or inducing the
expression of metalloproteinases, all of which contribute to the development of
cardiovascular disease (31).
In summary, disruptions of the oral microbiome are not only common, but can
result in debilitating and chronic diseases for patients in the oral cavity and at distal body
sites as well. Identifying novel ways to help prevent, manage, and treat such diseases
remains a focus for researchers and clinicians worldwide, with the use of probiotics
offering a promising avenue for tackling these conditions.

1.5

Probiotics
Probiotics are defined as live microorganisms that when administered in adequate

amounts confer a health benefit on the host (32). Of the many clinical studies showing the
ability of probiotics to prevent and treat local and distant site condition (32, 33), the
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effects are mostly strain specific. There are a number of ways in which probiotics interact
with the host, including competition with other organisms, epithelial cross talk with the
host immune system, improving the integrity of epithelial barriers and function of tight
junctions, and production of many metabolites, enzymes, co-factors, and vitamins K, B2,
B12, and folate, all of which are utilized by the host (33–38).

1.5.1 Probiotics for Dentistry
The ability of probiotics to help maintain a healthy oral cavity or manage and treat
oral diseases has been increasingly examined in recent years. As oral disease is the fourth
most expensive disease to treat worldwide (39), regular probiotic usage may offer the
opportunity to economically complement visits with trained dental professionals. Dental
caries, traditionally associated with the species Streptococcus mutans, has been targeted
by a variety of health-associated bacteria. Studies have demonstrated that consumption of
Lactobacillus rhamnosus in cheese (40), Lactobacillus reuteri in tablets/straws (41), and
Bifidobacterium in yogurt (42) are capable of reducing salivary S. mutans counts.
Interestingly, these Lactobacillus and Bifidobacterium species are usually recognized as
dietary probiotics aimed at improving gastrointestinal health, and have been derived from
the intestinal tract. As such, it has been suggested that using bacteria that traditionally
colonize the oral cavity may offer a better chance to impact oral health parameters. An
interesting strategy along this line has been designed by Hillman and coworkers, who
isolated a strain of S. mutans from a human subject capable of producing a bacteriocin
with potent activity against virtually all other S. mutans strains (43). This strain was able
to stably colonize the oral cavity of human volunteers, and resulted in an overall decrease
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of S. mutans levels (44). In an effort to reduce its cariogenic potential, this group
successfully deleted the lactate dehydrogenase operon from the bacterial genome, then
demonstrated that the resulting mutant strain resulted in a lower incidence of dental caries
development in rat infection models compared to the wild type strain (45). As lactic acid
production is presumed to be the driving pathogenic mechanism behind the development
of cariogenic lesions, this S. mutans strain offers intriguing potential for "replacement
therapy", where indigenous, potentially pathogenic bacterial species are eliminated from
their ecological niche and replaced with a strain designed to prevent oral damage (46).
Future oral probiotic development may be well served by following a similar approach;
identifying and isolating potential beneficial species from healthy volunteers, determining
colonization

potential,

and

engineering

the

strain

to

generate

favourable

products/eliminate harmful ones.
Another oral health related condition that has been tackled by probiotics is
halitosis (bad breath). Driven mainly by the production of volatile sulfur compounds
(VSCs) by bacteria (particularly Gram negative anaerobes, including P. gingivalis and
Prevotella intermedia) colonizing the tongue (47), it is believed to affect a large
proportion of the population to various degrees. Traditional treatment options have
focussed on the non-specific elimination of oral bacteria by various anti-bacterial
chemical therapies. However, such efforts are costly and provide short-term relief, as
malodour generating bacteria quickly return when treatment is ceased (48). In one
probiotic study, healthy individuals who gargled a solution containing a Weissella cibaria
isolate (selected based on its observed hydrogen peroxide generating ability in vitro) had
lower VSC levels the following day than those who gargled a solution of distilled water
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(49). Probiotics designed to treat periodontal disease have also been tested with
promising results. Teughels et al. recently examined the daily usage of lozenges
containing Lactobacillus reuteri by patients suffering from chronic periodontitis
following standard dental scaling and root planing (50). Probiotic consumption resulted
in significantly more pocket depth reduction and attachment gain in deep periodontal
pockets, as well as a decrease in P. gingivalis levels, compared to those subjects who
received a placebo lozenge. A similar study using Lactobacillus salivarius WB21containing tablets demonstrated the ability of this probiotic to reduce the plaque index
and periodontal pocket depth in subjects at high risk of periodontal disease (51).
While the above examples clearly demonstrate that a variety of bacterial species
and strains have been used successfully as probiotics in dentistry, our research focused
specifically on the oral species Streptococcus salivarius, and ways that it could be applied
to help maintain homeostasis in the oral cavity.

1.6

Streptococcus salivarius K12 and M18
Streptococcus salivarius is a Gram-positive bacterial commensal which colonizes

the human oral cavity throughout the host's life, and is generally associated with health
(52). These characteristics made this species attractive to investigate as a potential oral
probiotic. S. salivarius strains K12 and M18 were selected for further study based on
their in vitro inhibitory activity against Streptococcus pyogenes (53). Both strains encode
multiple bacteriocins; bacterially produced substances with the capacity to either inhibit
other bacteria attempting to colonize the same niche, or to act as signaling molecules. S.
salivarius K12 produces the bacteriocins Salivaricin A2 and Salivaricin B (54), while
M18 produces Salivaricin A2, Salivaricin 9, and the bacteriocin MPS (55). Studies have
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demonstrated that these S. salivarius strains are safe for human consumption (56), and
can colonize and persist in the human oral cavity (57, 58), particularly on the tongue
dorsum and other mucosal membranes. S. salivarius K12 has been shown in placebo
controlled studies to prevent recurrent Streptococcal induced pharyngitis in adults (20
patients receiving the probiotic for 90 days) (59) and children (45 patients receiving the
probiotic for 90 days, then a 6 month follow-up period) (60), as well as reduce halitosis
by limiting the production of volatile sulfur compounds from anaerobic bacteria (48). S.
salivarius M18 consumption was able to reduce dental plaque scores and S. mutans
numbers in children (61).
Given S. salivarius K12 and M18's successful ability in treating other oral
diseases, our group was interested if this probiotic species could be used to target
periodontal disease. Interestingly, a wide variety of Streptococci species have been
shown to exhibit anti-inflammatory effects on human cells. For example, Kaci et al. have
demonstrated that multiple S. salivarius and S. vestibularis isolates are capable of
inhibiting the inflammatory response of TNF-α stimulated intestinal epithelial cells (62),
and that intragastric administration of a live S. salivarius strain significantly inhibited
inflammation in severe and moderate colitis mouse models (63). Similarly, groups have
shown that S. salivarius, S. mitis, and S. sanguinis can reduce the release of the proinflammatory cytokine IL-8 from pathogen stimulated human cells (64, 65). As
periodontal disease is primarily inflammation driven, and S. salivarius K12 and M18
have a proven record of safety and efficient colonization in the human oral cavity, we set
out to determine whether these probiotic strains could potentially play a role in the
management of this disease.
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1.7

Hypothesis and Objectives
We hypothesize that Streptococcus salivarius strains K12 and M18 are capable of

modulating inflammation in the oral cavity.
The objectives of this thesis are to:
1. Characterize the ability of S. salivarius strains to interact with a variety of oral
microbes.
2. Investigate whether S. salivarius can modulate inflammatory factors produced by
human oral fibroblasts exposed to common dental pathogens.
3. Assess in humans the extent to which S. salivarius K12 administration can modulate
the oral microbiome and inflammatory mediators over the course of 14 days.
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Chapter 2
2

Materials and Methods

2.1

General Materials and Methods

2.1.1 Bacterial Growth Media
All bacteriological media types were prepared according to the manufacturer's
instructions, then sterilized by autoclaving at 121oC, 15 psi for 15 minutes.
2.1.2 Bacterial Strains - Origin
Streptococcus salivarius K12 and M18, Candida albicans TIMM 1768, as well as
the nine standard indicator strains used (I1 to I9) were kindly provided from the laboratory
collection of Dr J. R. Tagg (University of Otago, Dunedin, New Zealand). These were
Micrococcus luteus (I1), S. pyogenes M-type 52 (I2), Streptococcus constellatus (I3),
Streptococcus uberis (I4), S. pyogenes M-type 4 (I5), Lactococcus lactis ssp. lactis (I6), S.
pyogenes M-type 28 (I7), S. pyogenes M-type 87 (I8) and Streptococcus dysgalactiae (I9).
Aggregatibacter actinomycetemcomitans Y4 (AA), Porphyromonas gingivalis 33277
(PG), Fusobacterium nucleatum 10593 (FN), and Streptococcus mutans 25175 were
purchased from ATCC. Lactobacillus reuteri RC-14, Lactobacillus plantarum Lp-2001,
and Lactobacillus helveticus Lafti L10 were obtained from the Reid/Burton culture
collection.
2.1.3 Bacterial Strains - Storage and General Culture
Stock cultures were stored in 30% (v/v) glycerol in MRS (de Man, Rogosa and
Sharpe) broth (Lactobacilli species) or Brain Heart Infusion with Yeast Extract (BHYE)
broth (all other species) at -80oC, and regularly subcultured every two weeks on the
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appropriate solid media. Solid media was prepared in 10cm petri dishes. S. salivarius
K12 and M18, along with I1 to I9 were maintained on Columbia Blood Agar plates (CBA)
(Difco Columbia Agar Base [BD]) supplemented with 0.1% CaCO3 and 5% (v/v) sheep's
blood. L. reuteri, L. plantarum, and L. helveticus were maintained on MRS plates with
1.5% agar. Unless otherwise noted, these species were routinely grown at 37oC in 5%
CO2 in an anaerobic jar. C. albicans was cultured aerobically at 30oC on Sabouraud
Dextrose Agar. A actinomycetemcomitans, P. gingivalis, and F. nucleatum were grown at
37oC on BYHE with 1.5% agar in an anaerobic chamber containing 85% (v/v) N2, 10%
(v/v) H2, and 5% (v/v) CO2.
2.1.4 Primary Human Gingival Fibroblasts
Gingival fibroblasts were cultured from explanted tissue obtained from healthy
volunteers undergoing periodontal procedures in the Oral Surgery Clinic at UWO in
accordance with the guidelines of the University’s Research Ethics Board with informed
patient consent. Fibroblasts from four separate patients were used in this thesis, and were
routinely cultured in Minimum Essential Medium (MEM) supplemented with 10% FBS
and 100 mM L-glutamine, at 5% CO2 and 37oC. Fibroblast passages between 4-9 were
used for the studies. For experiments, fibroblasts were inoculated into the wells of a 24well plate and allowed to grow for 48 hours to reach confluency (approximately 5 x 105
fibroblasts per mL).
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2.2

S. salivarius Experiments in vitro

2.2.1 Simultaneous Bacterial Antagonism
Simultaneous bacterial antagonism assays were conducted as previously described
(53). Briefly, overnight cultures of pathogens of interest were swabbed evenly over the
surface of a blood agar plate. K12 and M18 colonies were then stab inoculated into the
agar. Plates were incubated for 48 hours at 5% CO2, then examined for zones of
inhibition.
2.2.2 Deferred Bacterial Antagonism
K12 or M18 were grown as a 1 cm wide streak on a blood agar plate for 18 hours.
The bacterial growth was then removed from the plate, with the surface of the plate then
sterilized for 20 minutes with chloroform vapour. After drying, indicator strains and oral
pathogens were streaked across the plate perpendicular to the original growth. The plate
was then incubated for 48 hours at 5% CO2, and examined for inhibitory activity.
2.2.3 Co-aggregation
To determine whether K12 and M18 could co-aggregate with the oral pathogens,
a qualitative visual assay was carried out. Overnight cultures of each bacterial strain were
centrifuged (10 minutes at 3000 x g), washed three times in PBS, then resuspended in
PBS to an equivalent Optical Density (1.0). Each periodontal pathogen was mixed with
an equal volume of the test S. salivarius strain. The turbidity of the mixture was then
recorded at 8 hours and given a score based on the observed aggregation. Known positive
(Candida albicans) and negative (Streptococcus mutans) controls were carried out as
well to act as a reference.
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2.2.4 Attachment to Host Cells
K12 and M18 were tested for their ability to adhere to cultured monolayers of
human gingival fibroblasts. Overnight bacterial cultures were centrifuged (10 minutes at
3000 x g), washed three times in PBS, then resuspended in fibroblast growth media and
added to the monolayers at a Multiplicity of Infection (MOI) of 25:1, and incubated for 8
hours. The monolayers were then washed three times with sterile PBS to remove nonadherent bacteria, then lysed with 0.1% Triton X-100. This concentration of Triton X-100
was tested to ensure it completely lysed all fibroblasts, while not affecting bacterial
viability. Remaining bacteria were then dilution plated on blood agar and allowed to
grow overnight at 5% CO2.
2.2.5 Pro-inflammatory Cytokine Release
Potential anti-inflammatory effects of S. salivarius K12 and M18 were examined
using a gingival fibroblast challenge model. Briefly, fibroblasts were added to the wells
of a 24 well plate and allowed to grow for 48 hours until they reached confluency. At this
point, cultures of either the probiotic, pathogen, or a combination of strains were added to
the fibroblasts at an MOI of 25:1. Bacteria were co-incubated with the fibroblasts for 8
hours. After this time period, the culture supernatant was collected, centrifuged to clear
debris, then stored at -20oC. Levels of the pro-inflammatory cytokines IL-6 and IL-8
were then determined using a Luminex multiplex immunoassay kit.
To determine whether S. salivarius K12 produced any soluble anti-inflammatory
factors, overnight K12 cultures were centrifuged, with the resulting supernatant filtersterilized, then applied to F. nucleatum stimulated fibroblasts for 8 hours. The level of
IL-8 secretion was then determined using a commercial IL-8 ELISA kit. K12 supernatant
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was also fractionated based on size (using a 10 kDa centricon filter), with both the <10
kDa fraction and >10 kDa tested on stimulated fibroblasts. Based on the fact that S.
salivarius is known to secrete some molecules to a higher degree when grown on a solid
surface, a freeze thaw extract from a K12 bacterial lawn was prepared. In this procedure,
an agar plate covered in bacterial growth is placed at -80oC for 4 hours, then allowed to
thaw with the resulting liquid collected from the degraded matrix and filter sterilized.
Finally, this freeze thaw extract was subjected to heat treatment (10 minutes at 80oC) and
trypsin digest (10 minutes).
2.3

C. albicans Experiments in vitro
Hyphae formation/C. albicans adhesion to 96-well plates was assessed after 3

hours, by fixation of cells in 70% ethanol, followed by crystal violet staining and OD600
reading as previously described (66). Sterile-filtered supernatant (SFS) collected from
select probiotic strains grown anaerobically for 22 hours in YEPD were mixed 50:50 with
YEPD (1% FBS), to maintain a constant concentration of FBS and YEPD between
conditions. Pooled, sterile-filtered human saliva was also used as a mixture in some
experiments. As well, previously established biofilms were washed carefully three times
with PBS, with plates then incubated for a further 3 hours with probiotic culture
supernatant mixtures, then assayed for attachment as before.

2.4

Pilot Study on the Effects of a Probiotic Gum on the Healthy Oral Cavity

2.4.1 Human Study Objective and Primary Outcome
The major objective of this section was to test our hypothesis that a protective
anti-inflammatory effect would be produced in the saliva of individuals consuming a
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probiotic gum tablet containing S. salivarius K12 bacteria. As such, our primary outcome
of interest was observing levels of several pro-inflammatory cytokines important in oral
disease conditions at various time points, and comparing these to levels in individuals
chewing regular, non-probiotic gum. Additionally, we wanted to determine how effective
S. salivarius K12 delivered in gum colonizes and persists in the oral cavity, and what, if
any, effects this gum would have on the established oral microbiome.
2.4.2 Ethics Statement
Details of the proposed pilot study were reviewed and approved by both the
Health Sciences Research Ethics Board at the University of Western Ontario (Appendix
1) and the Clinical Research Impact Committee at the Lawson Health Research Institute
(Appendix 2). Each participant received a package explaining the relevant details of the
study, were given the opportunity to have any questions of theirs answered, and signed a
letter of consent prior to the commencement of the study (Appendix 3).
2.4.3 Study Population and Recruitment
Recruitment of individuals between the ages of 20-60 years with general good
oral health took place in London, Ontario. Recruitment posters (Appendix 4) were placed
in the Lawson Health Research Institute, and emphasized a need for healthy individuals
interested in being part of a short, two week study. Communication between the study
coordinator and those interested in participating was carried out by phone and in person.
Participants were excluded if they had any oral disease, an oral implanted device, were
currently taking antibiotics, or had a dental appointment scheduled during the course of
the study.
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2.4.4 Study Design and Sample Collection
The study recruited twenty healthy adult volunteers, who were randomly assigned
into two groups containing 10 individuals each, matched for sex and age. Participants
received either probiotic CulturedCare™ with BLIS K12™ gum tablets (Group 1) or
regular gum tablets lacking probiotic bacteria (Group 2). CulturedCare™ gum tablets are
commercially available in Canada. Each individual was assigned a unique identifier code,
to ensure anonymity and that we would be blinded to which group a sample belonged too.
Both gum types were similar in taste, appearance, and texture. Participants were supplied
enough gum tablets to last the duration of the study. Over the course of the next 15 days,
participants followed the timeline detailed in the "Study Design Flowchart" (Appendix
5). On Day 1 of the study, participants brushed their teeth at 8:00 AM, then collected 3
mL of unstimulated saliva in a supplied 15 mL conical tube at 9:00 AM. This served as a
baseline sample for the participant. Individuals then chewed one gum tablet for 10
minutes, before discarding the material. This was the standard chewing procedure used
throughout the study. A second piece was chewed following tooth brushing at 8:00 PM.
On Days 1-7 participants followed this twice daily pattern of brushing/chewing. On Day
8 a "wash-out" period begun, where participants followed the same tooth brushing
pattern, but without gum tablet consumption. Additional saliva samples were collected at
1:00 PM on Day 1, and at 9:00 AM on Days 2, 8, and 15. These time points corresponded
to 4 Hours, 24 Hours, 7 Days, and 14 Days post first gum tablet exposure. All saliva
samples were delivered by the participants to the Burton lab at the Lawson Health
Research Institute where they were immediately aliquoted into 1.5 mL eppendorf tubes
and stored at -80oC until use.
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2.4.5 Salivary Pro-Inflammatory Cytokine Levels
Levels of pro-inflammatory cytokines (IL-6, IL-8, IL-1β, and IFN-γ) in the saliva
of subjects in the probiotic gum group were measured using multiplexed immunoassay
kits according to the manufacturers’ instructions (Bio-Rad Laboratories Inc., Hercules,
CA). A Bio-Plex 200 readout system was used (Bio-Rad), which utilizes Luminex®
xMAP fluorescent bead-based technology (Luminex Corporation, Austin, TX). Cytokine
levels (pg/mL) were automatically calculated from standard curves using Bio-Plex
Manager software (v. 4.1.1, Bio-Rad).
2.4.6 DNA Extraction and PCR Amplification
DNA was extracted from the saliva samples using the PowerSoil®-htp 96 Well
Soil DNA Isolation Kit (MoBio). The extraction was carried out as per the
manufacturer’s protocol, with two changes; the addition of a 10-minute incubation step at
65oC in a bead bath before the bead-beating step, and a doubling of the centrifugation
times. 500 µL of saliva were used for the extractions. In total, 94 samples were extracted
for sequencing.
Samples were PCR amplified for the V4 region of the 16S rRNA gene using
barcoded primers as follows: V4L (forward) 5’ GTGCCAGC[CA]GCCGCGGTAA 3’
and V4R (reverse) 5’ GGACTAC[ATC][ACG]GGGT[AT]TCTAAT 3’. Amplification
was carried out in a 42 µL reaction with 10 µL of each primer (3.2 pMol/µL stock), 20
µL GoTaq hot start colorless master mix (Promega) and 2 µL extracted DNA.
Thermocycling conditions were as follows: initial hot start activation at 95°C for 2 min,
then 25 cycles of 1 minute at 95°C for denaturation, 1 minute 55°C for primer annealing,
and 1 min at 72°C for extension.
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2.4.7 Sequencing and Read Processing
PCR products were quantified with a Qubit 2.0 Flourometer and high sensitivity
dsDNA specific fluorescent probes (Life Technologies). Samples were mixed at
equimolar concentrations and purified with the QIAquick PCR Purification kit
(QIAGEN). The pooled product was sent to the London Regional Genomics Centre
(LRGC) for sequencing on the Illumina MiSeq platform using the 600-cycle kit to
produce 2x300 paired-end reads. Using in-house Perl and Shell scripts, reads were
retained if sequence matched the primer while allowing 2bp mismatches, and with perfect
matches to expected sequence barcodes. Paired reads passing this filter were overlapped
using pandaseq (https://github.com/neufeld/pandaseq) (67) to produce full-length V4
sequences assigned by sample. Operational taxonomic units (OTUs) were constructed by
clustering

V4

reads

at

97%

sequence

identity

using

USearch

v.

7

(http://www.drive5.com/usearch/) (68). OTUs were retained if they represented at least
0.1% abundance of any one sample. The most abundant sequence in the cluster was used
as the reference sequence for taxonomic classification. The reference OTU sequences
were compared to the RDP database release 11.2 (https://rdp.cme.msu.edu) using
Seqmatch v. 3 (69), and the lowest common taxonomy was retained out of the top 20 hits
with an S_ab score ≥ 0.5. OTU sequences from differential taxonomic groups were
further validated by BLAST (70) against the Human Oral Microbiome Database
(HOMD) v. 13.2 (http://www.homd.org).
2.4.8 Statistical and Exploratory Analyses
The OTU table with assigned taxonomies was imported into QIIME
(http://qiime.org) (71) for exploratory analyses including summarizing reads to different
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taxonomic levels, generating beta diversity with weighted UniFrac distance (72) based on
OTU sequence alignment with MUSCLE (73), and principal coordinate analysis (PCoA).
Bar, stripchart, and PCoA plots were generated using R (74). Between-group
comparisons for differential microbiota analyses were conducted with ALDEx2 package
(http://www.bioconductor.org/packages/release/bioc/html/
ALDEx2.html) (75) in R. Taxonomic clusters were considered differential between
groups with an adjusted p-value ﹤ 0.01 using Welch’s t-test with Benjamini-Hochberg
multiple test correction, and with an effect size ≥ 1.5.
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Chapter 3
3

Results

3.1

S. salivarius Interaction with Oral Microbes

3.1.1 Bacterial Antagonism
The first step in this investigation was to determine whether S. salivarius K12 and
M18 could inhibit the growth of common oral bacterial species, especially those
associated with disease conditions. In a simultaneous antagonism assay, with the
probiotic of interest stab inoculated into an agar plate immediately after it had been
swabbed with a given indicator strain, both K12 and M18 failed to inhibit the growth of
P. gingivalis, F. nucleatum, A. actinomycetemcomitans, and C. albicans (Table 1).
However, they did demonstrate strong inhibition against indicator strains I1 to I9.
Additionally, a deferred antagonism assay was conducted to determine if initial
growth of a probiotic would result in the restriction of later indicator growth. Once again,
K12 and M18 demonstrated strong inhibition of strains I1 to I9, while having no effect on
growth of the four oral pathogens tested (Table 2).
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Producer Strain
S.
salivarius
K12 S. salivarius M18
Indicator Strain
P. gingivalis
F. nucleatum
A. actinomycetemcomitans
S. mutans
C. albicans
Micrococcus luteus (I1)
++
++
S. pyogenes M-type 52 (I2)
++
++
Streptococcus constellatus (I3)
++
++
Streptococcus uberis (I4)
++
++
S. pyogenes M-type 4 (I5)
++
++
Lactococcus lactis ssp. lactis (I6)
++
++
S. pyogenes M-type 28 (I7)
++
++
S. pyogenes M-type 87 (I8)
++
++
Streptococcus dysgalactiae (I9)
++
++
Table 1. Simultaneous Bacterial Antagonism. Inhibition after 48 hours of growth of S.
salivarius K12/M18 and indicator strain on agar plates. The zone of inhibition of the
indicator strain is indicated by: '-' no inhibition, '+' zone of inhibition diameter ≥ 3mm,
'++' zone of inhibition diameter ≥ 5mm. Results were consistent across the three
experiments conducted.
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Producer Strain
S. salivarius K12 S. salivarius M18
Indicator Strain
P. gingivalis
F. nucleatum
A. actinomycetemcomitans
S. mutans
C. albicans
Micrococcus luteus (I1)
++
++
S. pyogenes M-type 52 (I2)
++
++
Streptococcus constellatus (I3)
++
++
Streptococcus uberis (I4)
++
++
S. pyogenes M-type 4 (I5)
++
++
Lactococcus lactis ssp. lactis (I6)
++
++
S. pyogenes M-type 28 (I7)
++
++
S. pyogenes M-type 87 (I8)
++
++
Streptococcus dysgalactiae (I9)
++
++
Table 2. Deferred Bacterial Antagonism. Inhibition after 18 hours of S. salivarius
K12/M18 growth on agar plates, followed by 48 hours of incubation of the indicator
streaks. The degree of inhibition of the indicator streaks is noted by: '-' no inhibition, '+'
zone of inhibition is the same width as the producer streak, '++' zone of inhibition is at
least 1.5 times the width of the producer streak. Results were consistent across the three
experiments conducted.
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3.1.2 Bacterial Co-aggregation
The ability of the S. salivarius strains to interact with the same oral microbes
through co-aggregation was then examined. S. salivarius K12 and M18 displayed
identical co-aggregation patterns (Table 3). Both co-aggregated moderately well with P.
gingivalis and F. nucleatum, and weakly with A. actinomycetemcomitans. C. albicans coaggregated extremely strongly with the S. salivarius strains, while S. mutans
demonstrated no noticeable co-aggregation.
3.1.3 Bacterial Adherence to Human Oral Cells
Both S. salivarius K12 and M18 adhered to primary human gingival fibroblasts
after co-incubation for 8 hours (Figure 1). There was no significant difference in
attachment between the strains, with each resulting in approximately 30 bacterial cells
adhered per fibroblast at the endpoint. The level of adherence for S. salivarius was
significantly higher than demonstrated by L. reuteri, with less than 5 bacterial cells bound
per fibroblast. Finally, S. mutans did not adhere at all to the gingival fibroblasts.
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Pathogen

S. salivarius Strain
K12

PG
++

FN
++

AA
+

S. mutans
-

C. albicans
+++

M18

++

++

+

-

+++

Table 3. Bacterial Co-aggregation. Ability of S. salivarius K12/M18 to co-aggregate in
solution with various pathogens after 8 hours: “-“ no co-aggregation, evenly turbid
suspension; “+’”weak precipitation with evenly turbid supernatant; “++”moderate
precipitation with evenly turbid supernatant and evidence of flocculation;
“+++”substantial precipitation with clear supernatant and some flocculation. Results were
consistent across the three experiments conducted.

Bacteria/Fibroblast

60
50
40
30
20

*

10
0
K12

M18

L. reuteri
reuteriS.S.mmutans
utans
L.
Bacterial Species

Figure 1. Bacterial Adherence to Human Gingival Fibroblasts. Attachment of various
bacterial species to primary human gingival fibroblasts in vitro following 8 hours coincubation. Assay was carried out in triplet on three separate occasions.
(* p<0.05 compared to K12 attachment, unpaired t-test).
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3.1.4 Prevention of C. albicans Adherence
The ability of several oral probiotics to inhibit the binding of yeast to a solid
surface was explored. C. albicans was grown for three hours in the wells of a 96 well
plate in either pure growth media, or with a mixture of probiotic culture supernatants.
Microscopy was used to confirm that it was the hyphael form of C. albicans adhering to
the bottom of the plastic wells. After this period of growth the level of attachment of C.
albicans to the wells was determined using a crystal violet staining assay. The addition of
supernatant from both S. salivarius K12 and M18 significantly reduced adherence of C.
albicans to the wells (Figure 2). This was also observed with L. plantarum and L.
helveticus supernatants, which almost completely abolished C. albicans attachment.
Decreasing the amount of probiotic supernatant added (from 1/2 to 1/4 of the total growth
media) was less effective, but still resulted in significant attachment reduction.
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Figure 2. Adherence of C. albicans to 96-well Plates. Ability of C. albicans to attach to
the wells of a 96-well plate after 3 hours of incubation in YEPD (Control) or a mixture of
YEPD with either 1/2 or 1/4 bacterial culture supernatant. 'Neg. Ctrl': YEPD alone with
no C. albicans. (** p<0.01 compared to control, One-way ANOVA with Dunnett's
multiple comparison test).
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Based on the observation that the collected probiotic culture supernatants had a
lower pH than the normal C. albicans growth media, we wanted to determine if a lowered
pH could be solely responsible for the observed decrease in attachment. C. albicans was
therefore grown for 3 hours in the plastic wells in YEPD with the pH balanced to varying
levels between 4 and 9 (Figure 3). A clear trend was observed, with the lowest pH media
significantly reducing attachment. As such, the probiotic supernatants were pH balanced
to 7.0, with the same C. albicans adherence assay conducted. Balancing the pH of these
supernatants resulted in no significant attachment decrease for any of the tested probiotics
(Figure 4), suggesting that pH reduction of the supernatants by these probiotic strains is
the primary cause of the observed yeast attachment interference.
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Figure 3. Effect of pH on C. albicans Adherence. Attachment of C. albicans to a 96well plate after 3 hours of incubation in YEPD adjusted to various pH levels. (* p<0.05
compared to control, One-way ANOVA with Dunnett's multiple comparison test).
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Figure 4. Effect of pH-Balanced Probiotic Supernatants on C. albicans Adherence.
Attachment of C. albicans to a 96-well plate after 3 hours of incubation in a mixture of
YEPD with bacterial culture supernatants adjusted to pH 7.0.
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With the success of using non-pH balanced supernatant from individual probiotic
strains to decrease C. albicans adherence, we wanted to test whether using combinations
of these probiotics would result in similar, or perhaps even enhanced reduction. Using
combinations of S. salivarius M18, L. plantarum, and L. helveticus supernatants resulted
in a significant decrease in C. albicans adherence compared to the control (Figure 5).
This was the case regardless if the bacteria were grown together to produce a single
supernatant, or grown separately with their supernatants combined after the fact. The
addition of L. helveticus supernatant to a S. salivarius M18/L. plantarum mix resulted in
further, though non-significant, adherence reduction. While these combinations were
effective, they did not result in significantly lowered attachment compared to the use of
their individual strains alone, although this may be due to the minimum detection limit of
this assay. Of particular note, using supernatant from a C. albicans culture had no effect
on yeast attachment, suggesting that nutrient deprivation in the probiotic supernatants
was not an important factor.
Finally, in an effort to create an assay that more closely mimics conditions in the
oral cavity, we integrated the use of pooled, filtered human saliva into the C. albicans
attachment experiment. Adding saliva to either the regular growth media or C. albicans
culture supernatant resulted in a significant increase in yeast attachment (Figure 6). As
before, combinations of S. salivarius M18, L. plantarum, and L. helveticus supernatants
were able to significantly reduce C. albicans adherence to the wells, with the addition of
saliva not impeding this ability.
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Figure 5. Impact of Probiotic Combinations on C. albicans Adherence. Attachment of
C. albicans to a 96-well plate after 3 hours of incubation in a mixture of YEPD with
multiple, non-pH balanced bacterial supernatants. Growth media was 50% YEPD, 50%
supernatant (equal mixture of species). For growth conditions indicated by '+' in the bar
label, the probiotic species were grown overnight together in the same culture to produce
the resulting supernatant, rather than pooling supernatants from individually grown
species. (** p<0.01 compared to control, One-way ANOVA with Dunnett's multiple
comparison test).
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Figure 6. Effect of Saliva on Supernatant Mediated Reduction in C. albicans
Adherence. Attachment of C. albicans to a 96-well plate after 3 hours of incubation in a
mixture of YEPD and pooled, filter sterilized human saliva, combined with multiple,
bacterial supernatants. Growth media was 50% YEPD, 50% supernatant (equal mixture
of species), with an equivalent volume of saliva where indicated. For growth conditions
indicated by '+' in the bar label, the probiotic species were grown overnight together in
the same culture to produce the resulting supernatant, rather than pooling supernatants
from individually grown species. (* p<0.05, ** p<0.01 compared to control, One-way
ANOVA with Dunnett's multiple comparison test).
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3.1.5 Disruption of C. albicans Biofilms
While oral probiotic supernatants proved capable of preventing C. albicans from
attaching effectively to plastic wells, we were also interested if they could remove yeast
that had already adhered and formed a biofilm. C. albicans cultures were grown for 3
hours in regular growth media as before, then had the media carefully aspirated and the
wells washed briefly, before the addition of our probiotic supernatants of interest. The
presence of a thick yeast biofilm was confirmed by microscopy before the addition of the
supernatants. The plate was allowed to incubate for a further three hours, then assayed for
C. albicans attachment using the same crystal violet staining protocol. When compared to
the use of a C. albicans culture supernatant, combinations of S. salivarius M18, L.
plantarum and L. helveticus supernatant significantly reduced the amount of remaining
attached C. albicans (Figure 7).
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Figure 7. Disruption of C. albicans Biofilms by Probiotic Supernatants. Adherence of
pre-attached C. albicans to 96-well plates following 3 hour exposure to various bacterial
culture supernatants. For media conditions indicated by '+' in the bar label, the probiotic
species were grown overnight together in the same culture to produce the resulting
supernatant, rather than pooling supernatants from individually grown species. (* p<0.05,
** p<0.01 compared to control, One-way ANOVA with Dunnett's multiple comparison
test).
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S. salivarius Modulation of Inflammatory Factors
3.1.6 Pro-inflammatory Cytokine Release in vitro
The three periodontal pathogens (P. gingivalis, A. actinomycetemcomitans, and F.
nucleatum) were tested individually and in combination for their ability to stimulate the
production of pro-inflammatory cytokines in primary human gingival fibroblasts in vitro.
After co-incubation with the fibroblasts for 8 hours, all three significantly increased the
release of both IL-6 and IL-8 (Figure 8) compared to the no bacteria control. The
combination of three strains stimulated the most IL-6 production, while the triple
combination was not significantly different from P. gingivalis production in the case of
IL-8. In both cases A. actinomycetemcomitans was the least effective periodontal
pathogen at stimulating the release of these pro-inflammatory cytokines. In contrast,
exposing the fibroblasts to S. salivarius K12 or M18 did not result in any significant
differences in IL-6 or IL-8 (Figure 8) production compared to the control. The
concentration of cytokines produced was similar between both S. salivarius strains tested.
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Figure 8. Stimulation of Cytokine Production From Human Gingival Fibroblasts.
Concentration of IL-6 (A) and IL-8 (B) following 8 hour co-incubation of gingival
fibroblasts with various oral bacteria (* p<0.05, ** p<0.01 compared to control, One-way
ANOVA with Dunnett's multiple comparison test).

38

3.1.7 S. salivarius Reduction of Pathogen Driven Cytokine Release
Using the same in vitro model system with primary human gingival fibroblasts,
the oral probiotics S. salivarius K12 and M18 were tested for their ability to reduce
pathogen induced IL-6 and IL-8 production. The S. salivarius strains were applied either
simultaneously with the pathogens, or pre-incubated with the fibroblasts 30 minutes
before the pathogens were added. S. salivarius K12 and M18 were able to inhibit
pathogen induced IL-6 secretion (Figure 9A). Significant reductions were seen under all
conditions, with the exception of K12 pre- or co-incubated with P. gingivalis, and K12 or
M18 co-incubated with F. nucleatum. The S. salivarius strains were also effective at
reducing IL-8 secretion (Figure 9B), with significant reductions demonstrated for all
conditions with P. gingivalis, F. nucleatum, and the three pathogen combination.
Pretreatment

with

M18

also

significantly

reduced

IL-8

secretion

from

A.

actinomycetemcomitans stimulated fibroblasts. Importantly, under no circumstances did
the addition of the S. salivarius K12 or M18 increase the production of IL-6 or IL-8 from
pathogen stimulated fibroblasts.
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Figure 9. S. salivarius Reduction of Pathogen Stimulated Cytokine Release. Ability
of S. salivarius K12 and M18 to inhibit the production of IL-6 (A) or IL-8 (B) from
human gingival fibroblasts when co-incubated (K12/M18) or administered prior to
(K12P/M18P) oral pathogen exposure (* p<0.05, ** p<0.01 compared to control within
each pathogen group, One-way ANOVA with Dunnett's multiple comparison test).
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3.1.8 Mechanism of IL-8 Reduction
Attempts were made to elucidate the mechanism behind the ability of S. salivarius
K12 and M18 to reduce the production of pro-inflammatory cytokines from pathogen
stimulated human gingival fibroblasts. Based on patterns observed in previous
experiments, the choice was made to focus on S. salivarius K12 inhibition of F.
nucleatum induced IL-8 secretion. Once again, co-incubation of fibroblasts with F.
nucleatum resulted in significantly higher IL-8 production compared to the no bacteria
control, while K12 alone resulted in no significant changes (Figure 10). Likewise, adding
S. salivarius K12 to F. nucleatum reduced the IL-8 concentration back to a level not
significantly different than the control. Supernatant collected from an overnight S.
salivarius K12 culture had no effect on F. nucleatum induced IL-8 levels, nor did the >10
kDa fraction of this supernatant alone. However, the <10 kDa fraction of the supernatant
was effective at significantly reducing the IL-8 concentration. A freeze/thaw extract of S.
salivarius K12 grown as a lawn overnight on agar plates was also able to accomplish this.
While heat treatment of this freeze thaw extract had no effect on its activity, treatment
with trypsin abolished its anti-inflammatory properties.
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Figure 10. Mechanism of S. salivarius K12 Mediated IL-8 Reduction. Concentration
of IL-8 produced by human gingival fibroblasts after 8 hours under various conditions.
"Sup"= Supernatant, "FT"=Freeze/Thaw, "FN"=Stimulated with F. nucleatum (* p<0.05
compared to control, One-way ANOVA with Dunnett's multiple comparison test).
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3.2

Effect of Probiotic Gum Use in the Healthy Oral Cavity

3.2.1 Oral Microbiome Changes in Response to Chewing Gum
After filtering and clustering sequenced reads at 97% identity, there were 476
OTUs > 0.01% total abundance. A total number of 2,774,309 sequenced reads were
included for analysis, with a median of 29,779 ± 13,630 reads per sample. These OTUs
were further clustered by taxonomic lineage into 38 family groups of at least 0.05%
abundance across all samples. The most abundant taxonomic families detected at >10%
of total classified reads were: Porphyromonadaceae (17.95%), Pasteurellaceae (15.97%),
Prevotellaceae (15.85%), and Veillonellaceae (11.22%), apparent in Figure 11.
The weighted UniFrac distance is one method to determine the relatedness of
different microbiota. The distances between samples is relative to how similar the
composition of the microbiota are as weighted by the abundance of each organism
detected. Weighted uniFrac distances can be interpreted and plotted using principal
coordinate analysis (PCoA) as shown in Figure 12. The samples do not segregate by
group (probiotic vs control) in examination of the first 3 components, which explain
81.01% of the total variance in the data (top row, Figure 12). However, there is a distinct
shift in the first component over time, with many of the 7 day and 14 day samples
differentiating from the earlier time points (bottom row, Figure 12).
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hewing. Bacterial
Figure 11. Oral Microbiota Profiles Over Two Weeks of Gum Chewing
composition using V4 16S rRNA gene sequencing of saliva collected at five time points
for healthy volunteers chewing either S. salivarius K12 probiotic gum (top plot) or nonnon
probiotic (bottom plot) contro
controll gum. Each cluster of bars is an individual identified by a
subject ID number, and each bar in a cluster is an individual saliva sample ordered as
baseline, 4 hours, 24 hours, 7 days, and 14 days. The black bar indicates an uncollected
sample. Colours correspond
respond to the proportion of assigned taxonomic family (listed in the
legend on the right), ordered according to total abundance from bottom of the plot to top.
Groups of sequences that are less than 0.05% abundance across all samples, or less than
1% of sequences
equences in an individual are grouped as “rem”. Unclassified families are labeled
by their lowest classified taxonomic rank.
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UniF
Distance.
Figure 12. PCoA Plots for All Saliva Samples Based on Weighted UniFrac
Two dimensional PCoA plots representing the first three components of variation
between all saliva samples in the dataset. The first component in this analysis represents
the most variation explained in the data (in this case 60.49%), with subsequent
components representing
ng the next largest variance in the data. Distances between points
on the plot represent how similar samples are in terms of microbiota composition and
abundance.. Points on the plot that are closer in space are therefore more similar in their
taxonomic distribution.
tribution. The top and bottom row plots are identical,
identical differentially
coloured based on variable of interest (top - study group; bottom - sample collection time
point).
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To further examine the apparent time-dependent change in microbiota, the weighted
UniFrac distance of all time points from individuals in both treatment groups compared
to their baseline sample before treatment were plotted (Figure 13). The median weighted
UniFrac distance increases over treatment time indicating a shift in the microbiota.
Notably, a subset of the samples at 7 days and 14 days are very distinct from the others
(outlier points at the top of the plot in Figure 13, and to the right of the plot in Figure 12,
bottom row).
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Figure 13. Change in β-Diversity Measured by Weighted UniFrac Over Time.
Weighted UniFrac distance of each saliva microbiota sample compared to that
individual's baseline sample at 4 hours, 24 hours, 7 days, and 14 days. A value of 0 would
represent identical microbiota composition between samples, with a value of 1
representing maximal microbiota differences. Sample points are coloured by study group
(probiotic - red; control - blue). Lines represent the median UniFrac distance of a given
time point. Microbiota compositions change over time (regardless of study group), with a
subset of individuals changing drastically at 7 and 14 days.
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In order to test if there was any differential taxonomic abundances between
groups, a compositional data analysis framework was required (75). Therefore the
ALDEx2 toolset was employed to test for significant taxonomic difference between
groups at the family level. There were no differences (Benjamini-Hochberg adjusted pvalue >0.01) between the probiotic and control groups at baseline, between the probiotic
and control groups at study end-point (14 days), nor between these groups at any of the
other sample collection time points. Therefore, the treatment groups were pooled to test
for differences at end of study (14 days) compared to baseline. Presented in Table 4, there
were four family-level taxonomic groups with a relative increase in abundance, and three
with a relative decrease in abundance (Benjamini-Hochberg adjusted p-value <0.01 and
effect size ≥ 1.5). Examination of the OTUs in the family groups by BLAST to the
HOMDB revealed that most of the OTU sequences in Erysipelotrichaceae were similar
(>80% sequence identity) to Erysipelothrix tonsillarum (HOT_484) or Solobacterium
moorei (HOT_678).
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Family-level taxonomic group
Relative
increase

Relative
decrease

Firmicutes;Erysipelotrichia;Erysipelotrichales;Erysipelotrichaceae
Bacteroidetes;Bacteroidia;Bacteroidales;Porphyromonadaceae2
Bacteroidetes;Bacteroidia;Bacteroidales;Bacteroidaceae
Bacteroidetes;Bacteroidia;Bacteroidales;Porphyromonadaceae
Fusobacteria;Fusobacteria;Fusobacteriales;Leptotrichiaceae
Actinobacteria;Actinobacteria;Actinomycetales;Actinomycetaceae
Bacteroidetes;Bacteroidia;Bacteroidales;Prevotellaceae

Wt-BH*
1.85E-08
4.48E-08
5.25E-06
6.86E-07
1.39E-05
1.74E-05
1.34E-05

*Corrected p-value from a paired Welch’s t-test using Benjamini-Hochberg procedure
^The median effect size as estimated by ALDEx2

Table 4. Taxonomic Groups With Significant Changes in Relative Abundance.

Effect
Size^
2.04
1.87
1.57
1.51
-1.77
-1.61
-1.51
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3.2.2 Changes in Pro-Inflammatory Cytokine Levels
Concentrations of four pro-inflammatory cytokines linked with periodontal
disease were measured in the collected saliva of the nine subjects in the probiotic gum
group at each time point. These were all healthy individuals with no overt oral diseases,
however it has been demonstrated that everyone has some degree of these inflammatory
cytokines present in their saliva, as they are important for regular immune regulation.
Although cytokine concentrations were only measured for subjects chewing the probiotic
gum, the fact that a baseline saliva sample was taken allowed us to determine if exposure
to the probiotic would either raise or lower the amount of these cytokines. IL-8 levels
were the highest in the saliva samples (mean concentration 426.72 pg/mL for all samples
combined), while both IL-6 (8.32 pg/mL) and TNF-α (3.27 pg/mL) were present at much
lower concentrations (Figure 14). No significant differences were observed between the
concentration of a given cytokine when compared to another time point.
To determine if overall cytokine concentration variation between individuals was
obscuring the effects of probiotic gum consumption, fold changes in cytokines within
individuals were examined (Figure 15). However, no statistically significant differences
were observed when the fold changes for all probiotic gum chewers were compared for
any cytokine between any two time points.
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Figure 14. Salivary Levels of Pro-Inflammatory Cytokines. Concentration (pg/mL) of
IL-1β, IL-6, IL-8 and TNF-α (A-D) in collected saliva samples for the probiotic group at
five time points. Cytokine levels for each sample were determined individually, with the
mean concentration for all individuals plotted on these graphs. No significant differences
were observed for a given cytokine when comparing concentrations at any two time
points (One-Way repeated measures ANOVA).
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Figure 15. Fold Changes in Cytokine Concentrations. Baseline saliva cytokine levels
of IL-1β, IL-6, IL-8 and TNF-α (A-D) for every individual in the probiotic group were set
to 1, with fold-changes from baseline at each subsequent time point calculated and
plotted. No significant differences were observed for a given cytokine when comparing
concentrations at any two time points (One-Way repeated measures ANOVA).
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Chapter 4
4

Discussion
This thesis has demonstrated that oral strains of Streptococcus salivarius are

capable of interacting with other microbes known to cause disease in the oral cavity
through a variety of mechanisms, and can also influence pathogen-stimulated production
of inflammatory mediators. These are important findings, as in addition to characterizing
basic properties of this species central to its ability to colonize and persist in the oral
cavity, it included the first test of an S. salivarius probiotic strain's ability to modulate
salivary markers of inflammation in humans.
Bacteria in the oral cavity are known to adhere to surfaces and to each other in the
form of coaggregates and plaque biofilms. Given that no human has a sterile mouth, the
question is how do most individuals ensure inflammation and infection is minimal? For
many years, the simple presence, or increased abundance of certain bacterial species was
believed to be the driving cause behind many oral diseases. For example, Streptococcus
mutans was long presumed to be the primary etiological agent of caries (76), while
Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola (categorized
together as the "red complex") were closely linked with periodontal disease (77).
However, recent studies using high throughput sequencing techniques have shown that
these assumptions are over simplistic, with diseases often being polymicrobial in nature
(78, 79), and can even vary in microbial compositions between individuals (80).
Furthermore, a vast range of species are common constituents of both a healthy and
diseased oral cavity, including members of Pasteurellaceae and Prevotellaceae (10, 81).
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We confirm the high prevalence of these species in the saliva in our study performed on
19 orally healthy adults. Notably, Streptococcaceae were relatively abundant in these
subjects, and it is reasonable to assume that S. salivarius strains were among the species
detected in this family, as this species is the predominant commensal Streptococcus in the
oral cavity (82). While not conducted as part of this thesis, it would be possible to detect
and quantify S. salivarius K12 specifically by qPCR with targeted, validated primers, in a
manner similar to Burton et al. (83). This presence in healthy adults, as well as its known
early colonization of the oral cavity and the existence of various bacteriocins with potent
activity against common Gram-positive oral pathogens, has made it a species of potential
to recalibrate an aberrant oral microbiota, and thus suggests its use as a probiotic. Indeed,
the world's first two S. salivarius commercial probiotic strains, K12 and M18, were
selected for their ability to adhere, coaggregate and inhibit the growth of various
Streptococcus pyogenes species known to cause pharyngitis (84, 85).
Malodour, dental caries and gingivitis are symbolic of a dysbiotic oral
microbiome whose metabolic activities eventually lead to disease symptoms. Perhaps
even more concerning, it is the ability of these colonizing microorganisms to induce high
levels of inflammation that leads to pain, discomfort, and severe forms of periodontal
disease with subsequent loss of alveolar bone (86). We hypothesized that S. salivarius
may confer some immuno-modulatory activity in addition to its other beneficial
characteristics. To explore this, we used primary human gingival fibroblasts as an in vitro
model cell line, as they are in close contact with bacteria in subgingival plaque in
humans, and have been demonstrated as crucial for sustaining inflammation in
periodontal disease (87). We did indeed show that strains K12 and M18 were capable of
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reducing oral pathogen-induced IL-6 and IL-8 levels, two of the most notable indicators
of inflammation in this disease (25). This adds to a previous finding that showed antiinflammatory activity of K12, albeit against Salmonella and E. coli co-cultured with
human bronchial epithelial cells (64).
There are several means by which this activity could be beneficial in the oral
cavity. Firstly, the direct bacterial interaction with the epithelium could modulate
cytokines and reduce inflammation. This has been demonstrated for a S. salivarius strain
in the context of interaction with intestinal epithelial cells, with administration of live
bacteria also managing to alleviate inflammation in a mouse model of induced colitis (62,
63). Such an effect may be mediated by how the organism interacts with receptors such
as TLR2, or by interfering with the signal transduction pathways of the host cells (88),
either directly or through soluble by-products. We showed that a heat-stable, trypsinlabile component of the supernatant of K12 did indeed down-regulate pathogenstimulated IL-8 production. More work remains to be done to further isolate and
characterize this compound, as well as to determine what other molecules produced by S.
salivarius K12 may enhance or interfere with this compound's activity. This early work is
encouraging, and while this phenomenon has so far not been described elsewhere for S.
salivarius K12 specifically, it supports a finding by Sliepen et al. that supernatants from
S. salivarius, Streptococcus mitis, and Streptococcus sanguinis species were capable of a
similar effect (65). Importantly, we demonstrated this anti-inflammatory ability of K12
supernatant against F. nucleatum, which has traditionally been recognized as a
periodontal pathogen, and indeed has many pathogenic characteristics such as invasion of
epithelial cells and induction of inflammatory cytokines from host oral tissues (89). It
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might be argued that as S. salivarius is often located on the dorsal surface of the tongue
(58), it would not readily gain access to sub-gingival sites or be in high abundance there,
but its secreted by-products could still have an impact. If released into saliva, the
proteinaceous compound would be expected to be present in saliva for sufficient time to
reach different areas of the mouth. Proteins of similar size have been shown to persist in
the saliva and interact with a variety of bacteria and host cells (90). Of course, altering
IL-6 and IL-8 is not necessarily the only way that inflammation is driven, and we did not
test TNF-α or IL-1β, nor evaluate cellular immunity in this in vitro model. In addition,
some levels of IL-6 and IL-8 are necessary to maintain an immune system that protects
against infection (86), so the intent would not be to completely abolish them.
The ultimate test of these effects can only be achieved by human studies. In that
regard, we showed that the net effect on healthy subjects of exposure to K12 was to
maintain normal individual levels of IL-6 and IL-8, as these pro-inflammatory cytokines
did not increase or decrease in concentration compared to baseline levels when
individuals chewed the probiotic gum. This is an indicator of maintaining homeostasis,
and also safety of this probiotic. A future study could test this intervention on subjects
with known inflammation (for example, patients with moderate gingivitis or fixed
orthodontic appliances), and whose condition has not been alleviated by antimicrobial
agents.
Another way that these substances produced by K12 could be beneficial, is
through the organism's interaction with other bacteria. We showed that K12 and M18
coaggregate with pathogenic strains that are known stimulators of inflammation. It is
possible this coaggregation also played a role in reducing IL-6 and IL-8 levels. In other
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words, the probiotics either inhibited production of the inflammatory stimulants, or they
blocked their ability to trigger the host's reaction to them. It was outside the scope of this
thesis to examine these possibilities, but they are both worthy of investigation. K12 or
M18 could not inhibit actual production of lipotechoic acid or lipopolysaccharides, but it
may interfere with their binding to host cells. One way to test this would be to add LTA
or LPS to the streptococcal supernatant to see if there is inhibition.
In the human study, the volunteers brushed their teeth one hour before lozenge
use; it would have been interesting to see if there was an effect by not brushing, and
therefore allowing the K12 time to coaggregate with the existing biofilms, then see if an
anti-inflammatory effect was conveyed. This might have more aptly simulate our in vitro
experiments.
Another test of the mechanisms involved would be to allow the subjects to brush
their teeth then immediately apply the probiotic. This was done previously with strain
M18 in 75 volunteers (57). While this approach displaced the indigenous S. salivarius in
some subjects, Illumina sequencing of the V6 region of the 16S rRNA gene showed that
the overall composition of the oral microbiome was not modified. This is not unexpected
since brushing does not remove all plaque biofilms, but by displacing indigenous strains,
it may provide a more anti-inflammatory S. salivarius the opportunity to integrate into the
niche and reduce overall inflammation. This remains to be tested. If a more thorough
dental cleaning was undertaken (rather than simple brushing), it may be possible to have
S. salivarius probiotic strains better colonize, and then deplete re-adhesion of pathogens,
thereby also reducing the inflammatory processes. This is more of a competitive
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exclusion approach against the oral pathogens, and its potential has been demonstrated
for S. salivarius by others (61).
The findings with Candida albicans were also insightful for several reasons. Up
until now, the S. salivarius K12 strain had been shown to inhibit adhesion of C. albicans
to plastic surfaces and lower colonization in the mouth of rats (91). Our studies showed
that the interference with the yeast is not due to reducing growth, but rather it is due to
inhibiting hyphal formation and adhesion to surfaces. This makes sense ecologically, as
yeast are common inhabitants of a healthy mouth (17), but their abundance and
pathogenesis are kept in check by the indigenous microbiota and host immune status.
Although we did not use primers to detect C. albicans, none of the human volunteers had
evidence of yeast infection before or after probiotic use, indicating that the treatment did
not disrupt the inherent protective nature of the microbiota. However, our in vitro studies
showed that the K12 and especially M18 supernatant disrupted the yeast biofilms and
prevented transition to infectious hyphal form. This aligns with studies in the vagina,
where application of probiotic lactobacilli affected C. albicans metabolic activity, and
increased expression of stress-related genes (92).
The ability of oral probiotics to affect metabolic processes involved in infection
remain to be thoroughly studied. It remains unknown which metabolites are released en
masse by oral biofilms from healthy and non-healthy individuals, and how they influence
health and inflammation. If species such as S. salivarius somehow control the amount
and types of metabolic products, this would potentially make them a useful intervention
in people whose plaque biofilms are recalcitrant. Metabolic by-products have been
described in the oral cavity, for example hydrogen sulfide (H2S) gas produced by
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degradation of proteins in the subgingival pocket, which is highly toxic and believed to
have pro-inflammatory properties (93). It is one of the compounds associated with
halitosis. The alleviation of this condition by probiotic S. salivarius K12 (48) indicates
that the metabolism of pathogens is indeed affected. A range of amino acids, peptides,
lipids and carbohydrates can be detected in the mouth and are potentially markers for
decay (94). The culprits producing toxic metabolites in periodontitis appear to be P.
gingivalis, T. forsythia, and T. denticola (95). Ultimately, the concentrations of bacterial
metabolites are what causes symptoms and signs of disease, and stimulation of
inflammation. Therefore, a better understanding of which metabolites (microbial and/or
host) are influenced by probiotic application, and how these changes affect health of the
host, represent a key next series of studies that are warranted. Studies using
metatranscriptomics (96) along with metabolomics will be particularly insightful to
identify the organisms producing the toxic metabolites, and whether their genes are
suppressed by various treatments. This is the approach taken in our lab, where we showed
that Lactobacillus iners, present in the healthy vagina, adapts to the infectious bacterial
vaginosis (BV) emergence and higher pH, by altering its metabolic pathway (97), while
Gardnerella vaginalis produces compounds specific to the BV condition (McMillan et al.
submitted).
The human study provided two other interesting observations. Firstly, it
confirmed other recent studies showing a wide range of bacterial types present in the
saliva (10, 12, 81). This is transforming our view of the oral cavity and dental practice. It
was not long ago that S. mutans was taught in university classes to be the exclusive
etiological agent of caries, and that only a few pathogens were responsible for the
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majority of oral diseases. These had essentially followed the old microbiology concept of
Koch's Postulates (98), whereby a single organism caused a disease and this could be
reproduced by adding it back into the site. Rather, it is clear now that a wide range of
organisms, in most cases acting as a collective, create environmental conditions (low pH,
high sugars, toxins, inflammatory mediators) that result in diseases which present in a
clinically similar fashion.
Secondly, although the application of probiotics daily for a short seven days did
not appear to modulate the microbiota profiles of the volunteers, as has also been shown
with probiotic yogurt and the gut microbiota (99), there was some signs of shifts at day
14 regardless of whether the probiotic or control gum was being chewed. This was
surprising because it suggests that regular gum use can impact the oral microbiota, above
and beyond whether it contains sugar or not. It also demonstrated that the chewing action
per se over-rode the probiotic effect. We postulate that the xylitol present in both gums,
was responsible, as it has been shown to modulate the populations of cariogenic
streptococci (100, 101). Xylitol is a sugar alcohol which does not kill the probiotic strain
directly, but it may have caused a change in the coaggregated biofilms, such that it
affected adherence of the probiotic strain, and dislodged the clumps containing the
probiotic. Thus, it may be better to chew a xylitol gum, dislodge the biofilms, then chew
a probiotic gum (without xylitol) to re-calibrate the microbiota. Such a study is worthy of
investigation, although its practical implementation may be difficult since consumers are
not likely to do such a double-use of a gum product.
Alternatively, the human study simply showed that the probiotic application was
not effective, and the xylitol effects were artifacts. The latter is supported by a study of
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children in which xylitol did not disrupt the oral microbiota when chewed twice daily
(102). Clearly, other human studies are warranted, particularly in patients with chronic
diseases. If K12 or M18 were found not to be effective, it would question the importance
of bacteriocin production in inhibiting growth of pathogens. If studies confirmed that
K12 or M18 were effective, it need not be because they produce the bacteriocins. As
these bacteriocins are on mega-plasmids, removal of the plasmids would allow such
testing to occur. This has actually been achieved, and both K12 and M18 have been
produced without their plasmids (53). It would now be useful to assess the supernatants
of these strains to see if they affect pathogenic biofilms and inflammation. In that case, it
would be best to mimic plaque, caries or periodontal conditions, using a grouping of say
the ten most abundance pathogens found in these conditions. These are being identified
now through sequencing methodologies.
4.1

Overall Conclusions
This thesis has utilized a range of in vitro, high throughput sequencing and human

approaches to understanding how probiotic streptococci can be considered to improve
and maintain oral health. Both S. salivarius K12 and M18 appear to have characteristics
capable of interfering with bacterial and yeast pathogens in the mouth, and in addition to
modulating host inflammation responses. Both these strains are now sold in Canada and
other countries without any adverse effects. Given this, opportunities exist for dental
practitioners to monitor use of these products in a randomized, placebo-controlled
manner, to determine if clinical benefits are indeed accrued. From a mechanistic
perspective, more studies, as suggested herein, are warranted.
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